

MAY 11, 2023

OPEN ACCESS

**DOI:**  
[dx.doi.org/10.17504/protocols.io.81wgb676qlpk/v1](https://dx.doi.org/10.17504/protocols.io.81wgb676qlpk/v1)

**External link:**  
<https://doi.org/10.1371/journal.pone.0274065>

**Protocol Citation:** Timothy K. Soh, Susanne Pfefferle, Stephanie Wurr, Ronald von Possel, Lisa Oestereich, Toni Rieger, Maria Rosenthal, Jens B. Bosse 2023. A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.81wgb676qlpk/v1>

**MANUSCRIPT CITATION:**  
 Soh TK, Pfefferle S, Wurr S, Possel Rv, Oestereich L, Rieger T, Uetrecht C, Rosenthal M, Bosse JB (2023) A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells. PLoS ONE 18(5): e0274065. doi: [10.1371/journal.pone.0274065](https://doi.org/10.1371/journal.pone.0274065)

# A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells

Timothy K.

Soh<sup>1,2,3,4</sup>,

Susanne Pfefferle<sup>5,6</sup>, Stephanie Wurr<sup>5,7</sup>,  
 Lisa

Ronald von Possel<sup>5,8</sup>, Oestereich<sup>5,7</sup>, Toni Rieger<sup>5</sup>,

Maria Rosenthal<sup>1,5,9</sup>, Jens B. Bosse<sup>1,2,3,4</sup>

<sup>1</sup>Centre for Structural Systems Biology, Hamburg, Germany;

<sup>2</sup>Hannover Medical School, Institute of Virology, Hannover, Germany;

<sup>3</sup>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany;

<sup>4</sup>Leibniz Institute of Virology (LIV), Hamburg, Germany;

<sup>5</sup>Department of Virology, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany;

<sup>6</sup>University Center Hamburg-Eppendorf (UKE), Institute for Medical Microbiology, Virology and Hygiene, Hamburg, Germany;


<sup>7</sup>DZIF German Center for Infection research, Partner site Hamburg-Lübeck-Borstel-Riems;

<sup>8</sup>Department of Tropical Medicine and Infectious Diseases, Center for Internal Medicine, University of Rostock, Rostock, Germany;

<sup>9</sup>Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Discovery Research ScreeningPort, Hamburg, Germany

Maria Rosenthal: [rosenthal@bnitm.de](mailto:rosenthal@bnitm.de);

Jens B. Bosse: [jens.bosse@cssb-hamburg.de](mailto:jens.bosse@cssb-hamburg.de);



Jens B Bosse

**License:** This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working  
We use this protocol and it's working

**Created:** Jan 19, 2022

**Last Modified:** May 11, 2023

**PROTOCOL integer ID:** 57133

**Keywords:** SARS-CoV-2, herpes, HSV-1, HCMV, UV crosslinking, UV inactivation, inactivation validation

## ABSTRACT

Downstream analysis of virus-infected cell samples, such as reverse transcription polymerase chain reaction (RT PCR) or mass spectrometry, often needs to be performed at lower biosafety levels than their actual cultivation, and thus the samples require inactivation before they can be transferred. Common inactivation methods involve chemical crosslinking with formaldehyde or denaturing samples with strong detergents, such as sodium dodecyl sulfate. However, these protocols destroy the protein quaternary structure and prevent the analysis of protein complexes, albeit through different chemical mechanisms. This often leads to studies being performed in over-expression or surrogate model systems. To address this problem, we generated a protocol that achieves the inactivation of infected cells through ultraviolet (UV) irradiation. UV irradiation damages viral genomes and crosslinks nucleic acids to proteins but leaves the overall structure of protein complexes mostly intact. Protein analysis can then be performed from intact cells without biosafety containment. While UV treatment protocols have been established to inactivate diluted viral solutions, a protocol was missing to inactivate crude infected cell lysates, which heavily absorb light. In this work, we develop and validate a UV inactivation protocol for SARS-CoV-2, HSV-1, and HCMV-infected cells. A fluence of 10,000 mJ/cm<sup>2</sup> with intermittent mixing was sufficient to completely inactivate infected cells, as demonstrated by the absence of viral replication even after three sequential passages of cells inoculated with the treated material. The herein described protocol should serve as a reference for inactivating cells with these or similar viruses and allow for the analysis of protein quaternary structure from *bona fide* infected cells.

## GUIDELINES

This protocol was validated for 2x10<sup>6</sup> Vero E6 cells infected with SARS-CoV-2 at MOI 0.01, 5x10<sup>5</sup> Vero B4 cells infected with HSV-1 at MOI 3, and 2x10<sup>5</sup> HFF-1 cells infected with HCMV at MOI 3 in an individual 6-well.

## MATERIALS

phosphate-buffered saline (PBS)

Incidin Plus

infected cells

cell scraper

microcentrifuge tube

CryoELITE Tissue Vial (Wheaton, #W985100)

P1000 micropipette

microcentrifuge

UVP Crosslinker (CL-3000, Analytik Jena)

## SAFETY WARNINGS




Handle infectious materials within the appropriate containment facilities. Use UVP Crosslinkers in accordance with the manufacturer's guidelines.

## BEFORE START INSTRUCTIONS

Begin with infected cells in a 6-well plate.

### UV inactivate infected cells

- 1 Wash each well with 1 mL PBS 1m
- 2 Scrape each well ( $2 \times 10^6$  cells) into 1 mL PBS 1m
- 3 Transfer cells into a 1.5 mL tube 1m
- 4 Pellet cells at  16000 x g, 4°C, 00:01:00 1m
- 5 Resuspend cells in 200  $\mu$ L PBS 1m
- 6 Transfer cells to a tissue vial 1m

- 7 254 nm UV irradiation of vials 24m
  - 7.1 Irradiate vials with 2,500 mJ/cm<sup>2</sup> 5m
  - 7.2 Mix the cell solution with a micropipette 1m
  - 7.3 Repeat irradiation 3 additional times for a total of 10,000 mJ/cm<sup>2</sup> 18m
- 8 Screw the lids on the vials 1m
- 9 Disinfect the outside of the tissue vials by wiping with Incidin Plus 1m